The primary objective of bioprocess economics and cost analysis is to optimize the production process and minimize costs, thereby maximizing the profitability of the bioprocess.

Revenue is not a major component of bioprocess economics and cost analysis, as it is a measure of the income generated from the sale of products, rather than a cost or expense.

Capital costs refer to the initial investment required to establish a bioprocess facility, including the cost of equipment, machinery, and infrastructure.

Marketing and sales expenses are not typically considered operating costs in bioprocess economics and cost analysis, as they are related to the promotion and distribution of products, rather than the production process itself.

Fixed costs are those costs that remain constant regardless of the level of production, such as rent, depreciation, and insurance.

Raw materials are not typically considered fixed costs, as they vary with the level of production.

Variable costs are those costs that vary with the level of production, such as raw materials, utilities, and labor.

Equipment depreciation is not typically considered a variable cost, as it is a fixed cost that does not vary with the level of production.

Marginal costs refer to the additional cost incurred when producing one more unit of product.

Equipment depreciation is not typically considered a marginal cost, as it is a fixed cost that does not vary with the level of production.

Profit is the difference between the total revenue and the total cost of producing a product.

Increasing production to increase revenue is not typically a profit-maximizing strategy, as it can lead to higher costs and lower profit margins.

The break-even point is the point at which the total revenue equals the total cost of producing a product.

Cost-benefit analysis is not typically used to evaluate the feasibility of a bioprocess project, as it does not consider the time value of money.

The hurdle rate is the minimum acceptable rate of return on an investment.